← Back to Search

CAR T-cell Therapy

BCMA CAR-T cells treat for Multiple Myeloma

Phase 1 & 2
Recruiting
Led By Sanbin Wang, MD
Research Sponsored by Chongqing Precision Biotech Co., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse events that related to treatment
The response rate of BCMA CAR-T treatment in patients with relapse/refractory Multiple Myeloma that treatment by BCMA CAR-T cells therapy
Secondary study objectives
Duration of Response (DOR) of BCMA CAR-T treatment in patients with refractory/relapsed multiple myeloma
Levels of Cytokines in Serum
Overall survival(OS) of BCMA CAR-T treatment in patients with refractory/relapsed multiple myeloma
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: BCMA CAR-T cells treatExperimental Treatment1 Intervention
Patients will be be treated with BCMA CAR-T cells

Find a Location

Who is running the clinical trial?

Chongqing Precision Biotech Co., LtdLead Sponsor
38 Previous Clinical Trials
1,439 Total Patients Enrolled
3 Trials studying Multiple Myeloma
138 Patients Enrolled for Multiple Myeloma
Sanbin Wang, MDPrincipal Investigator920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
9 Previous Clinical Trials
477 Total Patients Enrolled
2 Trials studying Multiple Myeloma
98 Patients Enrolled for Multiple Myeloma
Cheng Qian, PhDPrincipal InvestigatorChongqing University Cancer Hospital
10 Previous Clinical Trials
485 Total Patients Enrolled
2 Trials studying Multiple Myeloma
120 Patients Enrolled for Multiple Myeloma
~12 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top